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Abstract
The limited efficacy of existing antiviral therapies for influenza – coupled with widespread baseline antiviral resistance –
highlights the urgent need for more effective therapy. We describe a triple combination antiviral drug (TCAD) regimen
composed of amantadine, oseltamivir, and ribavirin that is highly efficacious at reducing mortality and weight loss in mouse
models of influenza infection. TCAD therapy was superior to dual and single drug regimens in mice infected with drug-
susceptible, low pathogenic A/H5N1 (A/Duck/MN/1525/81) and amantadine-resistant 2009 A/H1N1 influenza (A/California/
04/09). Treatment with TCAD afforded .90% survival in mice infected with both viruses, whereas treatment with dual and
single drug regimens resulted in 0% to 60% survival. Importantly, amantadine had no activity as monotherapy against the
amantadine-resistant virus, but demonstrated dose-dependent protection in combination with oseltamivir and ribavirin,
indicative that amantadine’s activity had been restored in the context of TCAD therapy. Furthermore, TCAD therapy
provided survival benefit when treatment was delayed until 72 hours post-infection, whereas oseltamivir monotherapy was
not protective after 24 hours post-infection. These findings demonstrate in vivo efficacy of TCAD therapy and confirm
previous reports of the synergy and broad spectrum activity of TCAD therapy against susceptible and resistant influenza
strains in vitro.
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Introduction
Antiviral agents are an important therapeutic strategy for adults
and children infected with influenza, especially for those
hospitalized and at risk for severe illness such as the immuno-
compromised. While antiviral therapy has been demonstrated to
provide some benefit in this patient population [1,2,3,4], the
benefit – particularly with neuraminidase inhibitors – is only
realized if treatment is initiated within 48 hours of symptom onset,
and delaying treatment beyond this time frame is associated with
decreased efficacy and greater morbidity and mortality [4,5,6].
Furthermore, incomplete suppression of virus replication despite
antiviral therapy may result in the emergence of resistance, which
is correlated with high and prolonged viral replication such as
infection in immunocompromised patients [7,8], infections with
highly pathogenic avian A/H5N1 viruses [9,10] or primary
infection in young children [11,12,13]. In addition to treatment-
induced resistance, widespread baseline antiviral resistance in
circulating influenza virus strains further jeopardizes the effective-
ness of existing antiviral drugs. Virtually all influenza A viruses
circulating among humans at present are resistant to the
adamantanes (amantadine, rimantadine) [14], while seasonal A/
H1N1 viruses circulating immediately before the 2009 pandemic
were all resistant to the neuraminidase inhibitor oseltamivir [15].
Furthermore, oseltamivir resistance may emerge during treatment,
resulting in dual resistance in currently circulating adamantane-
resistant viruses [16,17]. Thus, there is an unmet need for new
treatment regimens that can provide greater clinical benefit to
those at highest risk of severe disease, and that can reduce the risk
of resistance development [7,8,9,10,11,12,13,14,15].
Given the limited therapeutic options at present, we chose to
optimize the use of available antivirals and to evaluate the
effectiveness of a triple combination antiviral drug (TCAD)
regimen consisting of amantadine (AMT), oseltamivir (OSL),
and ribavirin (RBV). We hypothesized that a combination of drugs
acting at different stages in the viral replication cycle might result
in synergistic antiviral activity. In earlier studies, we showed that
these drugs did indeed act synergistically in vitro against drug
susceptible viruses, with the triple combination showing greater
synergy than any of the double combinations evaluated [18]. In
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synergistic activity against AMT-resistant and OSL-resistant
influenza viruses [19]. AMT and OSL clearly contributed to the
synergy of the TCAD regimen at concentrations that were
clinically achievable and where these drugs had no activity as
single agents [19]. In the current study, we extend this work to
explore the in vivo efficacy and synergy of TCAD therapy in mice.
We found that TCAD therapy provided enhanced survival benefit
and reduced maximum body weight loss relative to all double
combinations in mice infected with fully susceptible, low
pathogenic influenza A/H5N1 and AMT-resistant 2009 A/
H1N1 viruses. Importantly, the activity of AMT was restored in
the context of the TCAD regimen against AMT-resistant influenza
strains, confirming earlier in vitro data [19]. These data
demonstrate the potential of TCAD therapy as a promising,
much needed approach to address the dual issues of limited
efficacy and antiviral resistance in the treatment of influenza
infection.
Results
Efficacy of TCAD in mice infected with wild-type and
AMT-resistant influenza
To evaluate the efficacy of TCAD in mice, we first optimized
the experimental parameters to recapitulate drug exposure and
timing of treatment in humans as closely as possible. To determine
the appropriate time point for drug administration in treatment
studies, the kinetics of influenza virus replication in mouse lungs
was determined using the low pathogenic A/H5N1 virus (A/
Duck/MN/1525/81). A time course of the virus titer in mouse
lungs demonstrated that peak titer occurred 24 hours after
exposure (Fig. 1A), indicative this time point was the appropriate
trigger for intervention. Next, we determined the drug regimens in
mice that would produce plasma exposures comparable to
humans. Pharmacokinetic data from single dose administration
of AMT, OSL, and RBV in humans and mice were obtained and
used to simulate the dosing regimens used in clinical studies
(Information S1). Due to species differences in the half-lives of all
three drugs, it is not possible to match peak (Cmax) and trough
(Cmin) plasma concentrations, but we were able to closely
approximate the area under the curve (AUC) and average
concentrations (Information S1). Based on the simulations, dosing
regimens of 46 mg/kg/day AMT, 25 mg/kg/day OSL, and
27 mg/kg/day RBV (all given in equal divided doses three time
daily) were determined to be the clinically relevant doses and were
used for murine efficacy studies.
To assess the relative potency of TCAD versus double- and
single-therapy, we investigated the survival benefit of TCAD and
double combinations and monotherapy in mice infected with
drug-susceptible A/H5N1 and AMT-resistant 2009 A/H1N1 (A/
California/04/09) influenza viruses. Placebo-treated mice infected
with either virus (N=20) all died or were sacrificed when they
reached $25% body weight loss (Fig. 1B and 1C). Eighteen of 20
(90%) A/H5N1-infected animals treated with TCAD survived
(Fig. 1B), which represented a survival benefit compared to
treatment with AMT/OSL (P=0.05), AMT/RBV (P=0.055),
and OSL/RBV (P,0.001) double combinations (Table 1).
Similarly, of mice infected with AMT-resistant 2009 A/H1N1
virus, 19 of 20 (95%) animals treated with TCAD survived
(Fig. 1C), which was a significant enhancement in survival benefit
relative to OSL/RBV and AMT/OSL (P,0.035, Table 2).
The efficacy of TCAD in reducing body weight loss during
infection with A/H5N1 or AMT-resistant 2009 A/H1N1
influenza viruses was also examined (Fig. 1D and 1E). Among
A/H5N1-infected mice, significant protection of maximum weight
loss relative to placebo was observed in those treated with AMT/
RBV or AMT/OSL combinations, but not in those receiving
combined OSL/RBV (Table 3). None of the monotherapy
regimens significantly reduced maximum weight loss. Greatest
protection against weight loss was observed in mice treated with
TCAD (P,0.001 compared to all double combinations, Table 3).
Against the AMT-resistant 2009 A/H1N1 virus, no significant
impact on maximum body weight loss was observed in mice
receiving monotherapy with AMT, OSL, or RBV relative to
placebo, while significant protection from weight loss was observed
for AMT/OSL but not OSL/RBV combinations (Table 4).
Greatest protection was seen in animals treated with TCAD,
which was significant compared to the AMT/OSL (P=0.019) and
OSL/RBV (P,0.001) double combinations. The percent weight
loss as a function of time for surviving mice infected with both
viruses and treated with the different antiviral regimens are
provided in Figures S1 and S2. The curves show a general trend
towards greater protection with the TCAD regimen compared to
double combinations. However, since the mice that die or were
sacrificed when they reached 25% weight loss were excluded, and
thus the number of mice in each group varied as a function of
time, no statistical analyses were performed.
Effectiveness of delayed treatment with TCAD
To assess the time dependence of the therapeutic benefit, we
examined the efficacy of delayed treatment in a lethal A/H5N1
mouse model by comparing survival in mice treated with TCAD
or OSL monotherapy at 4 hours pre-infection (-4 hours), or 24,
48, and 72 hours post infection. We found that TCAD was
strongly protective when administered up to 48 hours post-
infection, with survival rates of 100% when treatment was
initiated -4 hours or 24 hours after infection, and 93% when
treatment was begun 48 hours post infection (Fig. 2A). Partial
protection was provided when TCAD was administered 72 hours
after infection (53% survival). In contrast, OSL monotherapy was
partially protective only when initiated at -4 hours (47% survival)
and 24 hours post-infection (33% survival), and provided no
survival benefit when treatment was delayed to 48 or 72 hours
after infection (Fig. 2B). TCAD provided significantly greater
protection at all time points when compared to placebo or OSL
monotherapy (P,0.011 and P,0.008, respectively). Similar trends
were observed when maximum weight loss was evaluated as an
endpoint (Fig. 2C). Treatment with TCAD starting at -4 hours
and 24 hours post infection yielded strong protection from weight
loss compared to both placebo and OSL at the same time points
(P,0.001). While a smaller benefit was observed when adminis-
tered at 48 hours post infection, TCAD therapy nevertheless
provided greater benefit than both placebo and OSL (P,0.032).
The percent weight loss as a function of time for surviving mice
treated with TCAD or OSL at different time points relative to
infection are provided in Figure S3. Again, while the curves show a
general trend towards greater protection with the TCAD regimen
compared to OSL or placebo, especially with early drug
administration, no statistical analyses were performed due to the
fact that the number of mice in each group varied as a function of
time due to death.
Synergy of amantadine, oseltamivir, and ribavirin in vivo
To evaluate whether the synergy of TCAD seen in vitro is
maintained in vivo, we examined the dose response of AMT as a
single agent and in combination with fixed doses of OSL and RBV
in mice infected with either viruses. AMT was dosed at 15 and
46 mg/kg/day against AMT-susceptible A/H5N1, and at 46 and
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A/H5N1, AMT at 15 mg/kg/day as monotherapy was not
effective at preventing mortality or maximum weight loss (Fig. 3A
and 3B), whereas the clinically relevant dose of 46 mg/kg/day
resulted in a significant enhancement in survival benefit but had
no effect on weight loss. However, in combination with OSL/
RBV, treatment with AMT resulted in a dose-dependent increase
in survival benefit and inhibition of maximum weight loss, with the
15 mg/kg/day dose producing significant effects compared to
OSL/RBV alone, and the 46 mg/kg/day dose producing
significant effects compared to the low dose (Fig. 3A and 3B).
Against the AMT-resistant A/H1N1 virus, AMT monotherapy
had no impact on survival at 46 or 138 mg/kg/day (Fig. 3D). By
comparison, the addition of AMT at 46 mg/kg/day to clinically
relevant dose levels of OSL and RBV resulted in significantly
greater survival compared to treatment with OSL/RBV alone (19
of 20 versus12 of 20 mice respectively; P,0.001). Increasing the
AMT dose to 138 mg/kg/day in combination with OSL and
RBV resulted in survival of all treated mice (20 of 20 mice).
Similar dose-dependent effects on maximum weight loss were
observed (Fig. 3E). Relative to placebo, AMT monotherapy at 46
or 138 mg/kg/day had no effect on weight loss. In contrast, the
Figure 1. TCAD therapy is highly efficacious in mice. (A) The kinetics of A/H5N1 virus replication in mouse lungs. Mice were infected with an
LD100 dose of virus and the lungs were harvested at the indicated time points (N=5), homogenized, and the virus titer was determined by endpoint
titration in Madin-Darby canine kidney cells. Kaplan Meier survival curves for treatment of mice infected with lethal doses of (B) a drug susceptible A/
H5N1 influenza virus (A/Duck/MN/1525/81) and (C) AMT-resistant 2009 A/H1N1 influenza virus (A/California/04/09). Maximum weight loss analysis for
the treatment of mice infected with (D) drug susceptible A/H5N1 and (E) AMT-resistant 2009 A/H1N1. For this experiment, mice were treated with
AMT (46 mg/kg/day), OSL (25 mg/kg/day), and RBV (27 mg/kg/day) as monotherapies and in double or triple combinations at the same doses.
Treatments were given three times a day for 5 days starting 24 hours after virus challenge, and survival and body weight loss were monitored over 21
days.
doi:10.1371/journal.pone.0031006.g001
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significantly higher level of inhibition than in mice treated with
OSL/RBV alone (P,0.001). Increasing the AMT dose to
138 mg/kg/day in combination with OSL/RBV resulted in a
further reduction in maximum weight loss, which was significantly
greater than in mice treated with OSL/RBV (P,0.001) or with
OSL/RBV in combination with 46 mg/kg/day AMT (P=0.005)
(Fig. 3E). These data demonstrate that AMT was efficacious in
combination with OSL/RBV against the AMT-resistant virus at
doses which had no effect as monotherapy.
To further quantify the degree of interaction/synergy, the
percent weight change at day 5 post-infection was used as an
endpoint. The percent weight change at day 5 was used as this
represents the latest time point post infection in which most of the
mice in the placebo group were still alive, such that a linear dose
response model could be created that is not limited by the binary
nature of survival. Against A/H5N1, AMT treatment was
associated with a dose-dependent reduction of percent weight
change at day 5 both as monotherapy and in combination with
OSL/RBV (Fig. 3C), with each dose increase producing a
significant protection from weight loss (Table 5). Importantly,
the slope of the dose response for AMT in combination with OSL/
RBV was 1.8-fold greater than the dose response of AMT as a
single agent (P=0.058, Table 5), indicative of synergy. In mice
infected with AMT-resistant 2009 H1N1 virus, AMT produced no
effect on weight change at any dose as a single agent (Fig. 3F) and
the dose response slope was not different from zero (P=0.678,
Table 5). In contrast, AMT in combination with OSL/RBV
produced a dose-dependent reduction of percent weight change at
day 5, and each dose increase produced a significant reduction in
weight loss (dose effect P value,0.001). The enhanced efficacy of
AMT in combination with OSL/RBV is further supported by the
observation that the dose response slope for AMT in combination
with OSL/RBV was significantly greater than the slope for AMT
as a single agent (Table 5), demonstrating the synergy of the three
drugs in combination (see Information S1 for a derivation of
formulas to detect synergy based on dose effects).
Discussion
The availability of an antiviral therapy that has improved
potency over standard of care, has broad-spectrum activity against
the majority of influenza A strains regardless of the susceptibility,
and that can impede the emergence of de novo resistance would be
of high clinical utility. The pharmacologic rationale for the
development of a triple combination antiviral drug (TCAD)
composed of amantadine, oseltamivir, and ribavirin was that each
drug would target a different stage in the virus life cycle, thereby
maximizing the potential for synergy. In addition, given that
virtually all A/H3N2 and 2009 A/H1N1 influenza strains are
resistant to amantadine, and, in the 2008–2009 influenza season,
all seasonal A/H1N1 strains were resistant to oseltamivir, at least
two, and possibly three, drugs in the TCAD therapy will be active
against any of these viruses. A number of studies have evaluated
Table 1. Statistical comparison of Kaplan-Meier survival curves for treatment of mice infected with wild type A/H5N1 influenza.
Regimen (mg/kg/day) Survivors/Total
P value vs
Placebo
P value vs
AMT
P value vs
OSL
P value vs
RBV
P value vs
AMT/OSL
P value vs
AMT/RBV
P value vs
OSL/RBV
Placebo 0/20 ----- - -
AMT (46) 6/15 0.038 ---- - -
OSL (25) 0/15 0.675 ---- - -
RBV (27) 0/14 0.627 ---- - -
AMT (46)/OSL (25) 11/19 0.002 0.305 0.007 - - - -
AMT (46)/RBV (27) 12/20 0.001 0.274 - 0.008 - - -
OSL (25)/RBV (27) 1/20 0.583 - 0.925 0.985 - - -
AMT (46)/OSL (25)/RBV (27) 18/20 ,0.001 - - - 0.050 0.055 ,0.001
(-) No statistical comparison performed.
doi:10.1371/journal.pone.0031006.t001
Table 2. Statistical comparison of Kaplan-Meier survival curves for treatment of mice infected with AMT-resistant 2009 A/H1N1
influenza.
Regimen (mg/kg/day) Survivors/Total
P value vs
Placebo P value vs AMT
P value vs
OSL
P value vs
RBV
P value vs AMT/
OSL
P value vs OSL/
RBV
Placebo 0/20 - - - - - -
AMT (46) 0/9 0.090 - - - - -
OSL (25) 2/10 ,0.001 - - - - -
RBV (27) 0/10 0.002 - - - - -
AMT (46)/OSL (25) 10/20 ,0.001 ,0.001 0.185 - - -
OSL (25)/RBV (27) 12/20 ,0.001 - 0.071 0.001 - -
AMT (46)/OSL (25)/RBV (27) 19/20 ,0.001 - - - 0.017 0.035
(-) No statistical comparison performed.
doi:10.1371/journal.pone.0031006.t002
Triple Combination Drug for Influenza Infection
PLoS ONE | www.plosone.org 4 January 2012 | Volume 7 | Issue 1 | e31006double combinations of antivirals in vitro and in vivo with mixed
results of synergy [20,21,22,23,24,25,26,27,28,29]. More recently,
we and others have demonstrated that double combinations of
neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir)
were antagonistic in vitro and in humans [19,30].
Combination treatment with AMT, OSL, and RBV was highly
efficacious in preventing weight loss and death in mice infected
with drug-susceptible A/H5N1 and AMT-resistant 2009 A/H1N1
influenza viruses. The efficacy of TCAD was superior to treatment
with single drugs or any of the dual combinations, and the
enhanced potency of AMT combined with OSL and RBV in vivo
confirmed the synergy detected in vitro [18,19]. While comparisons
of the efficacy of TCAD versus dual drug regimens approached
but failed to reach statistical significance using mortality as an
endpoint in a couple of instances (Table 1), the totality of the data
support the conclusion that TCAD is superior to all the double
combinations. Using both endpoints of mortality and weight loss,
the P-values for all the comparisons between TCAD and the
double combinations ranged from 0.055 to ,0.001. The dose
dependent contribution of AMT to efficacy of TCAD therapy in
mice infected with 2009 A/H1N1 virus indicates that AMT
activity against drug-resistant virus was restored when combined
with OSL and RBV, consistent with in vitro studies [19].
Furthermore, the beneficial effects of TCAD therapy against A/
H5N1 virus were still observed when treatment was delayed to up
to 72 hours after infection. Importantly, the dosing regimens used
in our murine studies were designed to produce drug exposures
similar to those achieved clinically in humans, and were based on
pharmacokinetic data obtained for all three drugs in mice and
humans. Based on pharmacokinetic data in mice, we determined
from simulation that administration of the drugs three time daily
were required in order to approximate the plasma exposures in
humans, thereby ensuring predictiveness of the drug response (see
Information S1).
While the toxicity of the three-drug combination in mice was
not directly ascertained in these studies, we have determined the
toxicity of the drugs as single agents and have shown that the
drugs do not produce detectable toxicity as single agents at the
doses used in these studies (data not shown). Furthermore, the
doses of all three drugs used in these studies were 5- to .300-fold
below the 50% lethal doses of each individual drug [31,32,33].
The fact that at the highest dose of TCAD tested (138 mg/kg
AMT, 25 mg/kg OSL, and 27 mg/kg RBV) all mice survived
whereas none of the mice in the placebo groups survived
(Figure 3), and the fact that all mice in TCAD treated groups
gained weight during the course of treatment, clearly indicates
that any possible toxic effects did not affect our measures of
efficacy (e.g. mortality and weight loss).
In the mouse models of infection utilized for these studies,
mortality and weight loss were the primary and secondary
endpoints, respectively. The mouse infection model was designed
as a lethal model, wherein the inoculum was titrated to produce
complete lethality – preceded by significant weight loss – in the
untreated group within 5 to 7 days. In this model, mortality and
Table 3. Statistical comparison of percent maximum weight loss for treatment of mice infected with wild-type A/H5N1 influenza.
Regimen (mg/kg/day)
Mean Maximum
Weight Loss (%)
P value vs
Placebo
P value
vs AMT
P value
vs OSL
P value
vs RBV
P value
vs AMT/OSL
P value vs
AMT/RBV
P value vs
OSL/RBV
Placebo 225.0060.06 - - - - - - -
AMT (46) 223.6262.12 0.117 - - - - - -
OSL (25) 225.0060.00 0.988 - - - - - -
RBV (27) 224.9760.83 0.984 - - - - - -
AMT (46)/OSL (25) 221.6263.67 ,0.001 0.024 ,0.001 - - - -
AMT (46)/RBV (27) 222.2563.16 0.117 0.117 - 0.002 - - -
OSL (25)/RBV (27) 224.7860.93 0.794 - 0.797 0.825 - - -
AMT (46)/OSL (25)/RBV (27) 217.5864.38 ,0.001 - - - ,0.001 ,0.001 ,0.001
(-) No statistical comparison performed.
doi:10.1371/journal.pone.0031006.t003
Table 4. Statistical comparison of percent maximum weight loss for treatment of mice infected with AMT-resistant 2009 A/H1N1
influenza.
Regimen (mg/kg/day)
Mean Maximum
Weight Loss (%)
P value vs
Placebo
P value vs
AMT
P value vs
OSL
P value
vs RBV
P value vs
AMT/OSL
P value vs
OSL/RBV
Placebo 225.0060.00 - - - - - -
AMT (46) 225.0060.00 1.000 - - - - -
OSL (25) 224.8560.34 0.902 - - - - -
RBV (27) 225.0060.00 1.000 - - - - -
AMT (46)/OSL (25) 221.6365.87 ,0.001 0.009 0.009 - - -
OSL (25)/RBV (27) 223.1162.42 0.060 - 0.155 0.123 - -
AMT (46)/OSL (25)/RBV (27) 219.2763.50 ,0.001 - - - 0.019 ,0.001
(-) No statistical comparison performed.
doi:10.1371/journal.pone.0031006.t004
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us to obtain statistically significant ‘clinical’ efficacy measures using
a manageable number of animals. As such, mortality and weight
loss were used as the pre-specified endpoints in the experimental
design and statistical analysis plan. For these reasons, measure-
ment of viral titers was not considered in the design of the
experiments. While viral lung titers might provide additional
information, this would require the design and validation of an
alternative non-lethal robust model, i.e. one that mimics viral titers
and kinetics of human infection, and the dynamic range, effect
size, and variability need to be sufficiently validated for antiviral
studies.
Figure 2. The effects of delayed treatment in mice. Mice were infected with A/H5N1 and treated with (A) TCAD therapy or (B) OSL
monotherapy. Treatments were given three times a day for 5 days starting at -4 (prophylaxis), 24, 48, or 72 hours after virus challenge, and survival
and (C) maximum body weight loss were monitored over 21 days. Mice were treated with OSL (25 mg/kg/day) alone, or TCAD [AMT (46 mg/kg/day),
OSL (25 mg/kg/day), and RBV (27 mg/kg/day)]. *P,0.05 versus placebo; *** P,0.05 versus OSL at the same treatment time point.
doi:10.1371/journal.pone.0031006.g002
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treatment is achieved remains unclear, as is the related mechanism
by which AMT activity is restored in TCAD against AMT-
resistant 2009 A/H1N1. As AMT and OSL target different viral
surface proteins – the M2 ion channel and neuraminidase,
respectively – it is conceivable that protein-protein interactions are
affected by binding of the two drugs at the same time. Interactions
between M2 or NA and hemagglutinin, the receptor-binding
surface protein, have been shown to affect susceptibilities to AMT
and OSL respectively [34,35]. The presence of the third drug,
RBV, is clearly essential for the synergistic antiviral efficacy of
TCAD. RBV, which is licensed for hepatitis C and not influenza
Figure 3. The activity of AMT is enhanced in combination with OSL and RBV against drug susceptible and resistant viruses. (A,B,C)
Mice infected with AMT-susceptible A/H5N1 were treated with escalating doses of AMT (0, 15, and 46 mg/kg/day) either as a single agent or in the
context of TCAD therapy (with 25 mg/kg/day OSL and 27 mg/kg/day RBV). (D,E,F) Mice infected with AMT-resistant 2009 A/H1N1 were treated with
escalating doses of AMT (0, 46, and 138 mg/kg/day) either as a single agent or in the context of TCAD therapy. Kaplan-Meier survival curves for (A) A/
H5N1 or (D) 2009 A/H1N1 infection. *P,0.05 versus no AMT, ***P,0.05 versus low dose AMT. Distribution of maximum body weight loss over the
course of infection for (B) A/H5N1 influenza or (E) 2009 A/H1N1 influenza. Data bars represent median +/2 interquartile range. The mean percentage
weight change at day 5 in mice infected with lethal doses of (C) A/H5N1 influenza and (F) 2009 A/H1N1 influenza. Data bars represent mean +/2
standard deviation.
doi:10.1371/journal.pone.0031006.g003
Table 5. Slopes of the dose response for AMT as a single agent and in combination with OSL/RBV based on percent weight
change at day 5.
Virus Regimen Slope Estimate Standard Error P-value Versus Zero P-value Between Curves
Wild-type H5N1 AMT alone 0.1311 0.0335 ,0.001 0.058
AMT with OSL/RBV 0.2203 0.0322 ,0.001
AMT-resistant 2009
H1N1
AMT alone 20.0024 0.0058 0.678 ,0.001
AMT with OSL/RBV 0.0478 0.0078 ,0.001
doi:10.1371/journal.pone.0031006.t005
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of action, both virus- and host-directed, which are not clearly
delineated [36]. For example, RBV greatly enhances the potency
of interferon for treatment of hepatitis C virus infections, while
having marginal activity as a single agent against this virus [37].
Our data suggest that combined therapy with amantadine,
oseltamivir, and ribavirin may be an effective and viable
therapeutic option for the treatment of drug susceptible and
resistant influenza infection. A large randomized controlled trial
(NCT01227967) of TCAD therapy versus oseltamivir is currently
ongoing in patients at high risk for serious complications from
influenza infection, where there is clearly an unmet need for more
effective influenza treatment.
Materials and Methods
Viruses
The drug-susceptible avian influenza A/H5N1 virus (A/Duck/
MN/1525/81 (H5N1)) was provided by Dr. Robert Webster (St.
Jude Children’s Research Hospital, Memphis TN). It was passaged
once in Madin-Darby canine kidney cells (MDCK, ATCC catalog
no. CCL034) and three times in mice. The mouse adapted AMT-
resistant pandemic influenza A/H1N1 virus (A/California/04/09
(H1N1)) was provided by Dr. Elena Govorkova (St. Jude Children’s
Research Hospital).The viruswasfirstpassagedinMDCKcellsand
then grown in embryonated chicken eggs. It was then adapted to
mice by 9 sequential passages, and then plaque purified in MDCK
cells and amplified in embryonated chicken eggs. The virus was
then grown in MDCK cells to prepare viral stocks. Sequence
analysis was performed to confirm the presence of the AMT
resistance-associated S31N substitution in the M2 channel.
Antiviral drugs
Amantadine hydrochloride (AMT) was obtained from Moehs
Catalana S.L. (Barcelona, Spain). Ribavirin (RBV) was obtained
from BASF Pharma (Evionnaz, Switzerland) or Bidachem S.P.A
(Italy). Oseltamivir phosphate (OSL) was obtained from Dyna
International (Huaian) Co., Ltd. (China) or from Cipla Ltd.
(Mumbai, India). All drugs were completely dissolved and
administered in sterile water. Double and triple combinations were
co-formulated and administered as a single solution. The placebo
(sterile water) was administered in parallel with antiviral treatments.
Murine experiments
All animalexperimentsinthisstudywereconductedinaccordance
with the approval of the Institutional Animal Care and Use
Committee of Utah State University (approval # 552). The work
was performed in the University’s AAALAC accredited Laboratory
Animal Research Center in accordance with the National Institutes
of Health Guide for the Care and Use of Laboratory Animals
(Animal Welfare Assurance Number A3801-01).
Six-week-old female BALB/c mice from Charles River
Laboratories (Wilmington, MA) were anesthetized by intraperito-
neal injection of ketamine and infected intranasally with 50-ml
suspension of AMT-resistant A/California/04/09 (H1N1) influ-
enza or 90-ml suspension of susceptible A/Duck/MN/1525/81
(H5N1) influenza virus (see Supporting Information for virus
passage history). Each mouse received approximately 1610
4
CCID50 of virus (46 LD50) to achieve 100% lethality. For most
experiments, treatments were begun 24 hrs after infection and
administered three times a day (TID) for a total of 5 days by oral
gavage. For all studies, the clinically relevant dosage of each drug
(AMT 46 mg/kg/day, RBV 27 mg/kg/day, OSL 25 mg/kg/day)
was used alone and in combination, and was projected from
animal pharmacokinetic measurements as described in the
Supporting Information to provide plasma exposures in mice
similar to those in humans. In addition, a 3-fold lower and higher
dose of AMT (15 mg/kg/day and 138 mg/kg/day, respectively)
was used alone and in combination for some studies. For the
delayed treatment experiment, treatments began 4 hrs pre-
infection or 24, 48 or 72 hrs after infection. Mice were monitored
for 21 days, and mice showing body weight loss of 25% or more
from baseline were sacrificed. For the maximum weight loss
analyses, mice that died naturally or were sacrificed when they loss
$25% body weight were assigned a weight loss of 225%.
Statistical analysis
The primary endpoint for the mouse studies was survival benefit
and the secondary endpoint was the percent change in weight
from baseline (maximum and at day 5). The survival distributions
were estimated using Kaplan-Meier analysis and pairwise
comparisons were made using the Cox proportional hazards
regression model. Pairwise comparisons of the maximum percent
change in weight and percent change in weight at day 5 were done
using a one way analysis of variance (ANOVA) model. To evaluate
the interaction of AMT in combination with OSL and RBV, the
dose-response relationship for AMT alone was compared to the
dose-response relationship for AMT with OSL/RBV using weight
change at day 5. Using both sets of data, a regression model with
separate intercepts and slopes for AMT and AMT/OSL/RBV
was fit. Based on this model, a two-sided t-test was then used to test
equality of slopes, where equal slopes corresponds to no
interaction, positive slope difference corresponds to the presence
of an activity enhancement, and a negative slope corresponds to an
activity decrement (see derivation in Information S1). For mice
that died before day 5, the weights at day 5 were imputed using
weights from previous days to fit a linear regression model with
weight as the dependent variable and day as the independent
variable. The estimated intercept and slope from this model was
used to compute a predicted weight at day 5.
Supporting Information
Figure S1 Effects of antiviral treatment on weight loss
in surviving mice infected with A/Duck/MN/1525/81
(H5N1). For this experiment, mice were treated with AMT
(46 mg/kg/day), OSL (25 mg/kg/day), and RBV (27 mg/kg/
day) as monotherapies and in double or triple combinations at the
same doses. Treatments were given three times a day for 5 days
starting 24 hours after virus challenge, and survival and body
weight loss were monitored over 21 days. (A) Single agents. (B)
Combination regimens.
(DOC)
Figure S2 Effects of antiviral treatment on weight loss
in surviving mice infected with A/California/04/09
(H1N1). For this experiment, mice were treated with AMT
(46 mg/kg/day), OSL (25 mg/kg/day), and RBV (27 mg/kg/
day) as monotherapies and in double or triple combinations at the
same doses. Treatments were given three times a day for 5 days
starting 24 hours after virus challenge, and survival and body
weight loss were monitored over 21 days. (A) Single agents. (B)
Combination regimens.
(DOC)
Figure S3 Effects of antiviral treatments administered
at varying time points on weight loss in surviving mice
infected with A/Duck/MN/1525/81 (H5N1). For this
experiment, mice were treated with TCAD [AMT (46 mg/kg/
Triple Combination Drug for Influenza Infection
PLoS ONE | www.plosone.org 8 January 2012 | Volume 7 | Issue 1 | e31006day), OSL (25 mg/kg/day), and RBV (27 mg/kg/day)] or OSL as
monotherapy (25 mg/kg/day). Treatments were given three times
a day for 5 days starting at the indicated time point relative to virus
challenge, and survival and body weight loss were monitored over
21 days. (A) 4 hours pre-infection. (B) 24 hours post-infection. (C)
48 hours post-infection. (D) 72 hours post-infection.
(DOC)
Information S1 Correlation of doses in mice to human
exposure, and mathematical derivation of synergy as determined
by dose response relationships.
(DOC)
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